ARUP Laboratories Innovates Detection of Influenza A (H5) Virus
ARUP Laboratories is proud to announce the launch of a highly advanced assay designed specifically for the detection and subtyping of the influenza A (H5) virus. This breakthrough testing capability is crucial for assessing individuals who might have been exposed to the highly pathogenic avian influenza A (H5N1), often referred to as bird flu.
Importance of the New Assay
The emergence of H5N1 outbreaks has raised significant concern. An outbreak was detected among poultry and cattle herds earlier this year, highlighting that while the disease predominantly affects birds and livestock, human cases can occur. The CDC reports 66 confirmed human cases of bird flu in recent times, including severe incidents necessitating hospitalization.
Understanding the Threat
Experts emphasize that it remains vital for clinicians to stay vigilant in monitoring this growing health concern. Most identified cases of this virus stem from contact with infected animals. Benjamin Bradley, MD, PhD, the medical director at ARUP, noted that while human-to-human transmission has not yet been observed in the current outbreak, ongoing observation and testing are essential.
Collaboration with CDC
ARUP's new test, named Influenza A (H5) Virus by Qualitative NAAT, has undergone rigorous validation in cooperation with the CDC. This association was notably strengthened when ARUP was selected as one of only five formal partners with the CDC for developing avian influenza tests. Collaboration ensures that the testing methods are constantly updated to meet the emerging needs of public health.
Commitment to Public Health
ARUP's proactive approach includes continuous monitoring of the influenza A (H5) situation as it progresses. Their commitment to providing accurate and timely laboratory services positions them as a national reference laboratory, significant in the fight against emerging pathogens.
Future of Influenza A (H5) Testing
The newly developed assay represents a vital addition to testing options, enabling immediate and precise evaluation of suspected cases. This forward-looking approach amplifies ARUP's role in the public health landscape as they stand ready to tackle evolving challenges posed by influenza and other infectious diseases.
About ARUP Laboratories
Founded in 1984, ARUP Laboratories serves as a leading national reference laboratory. This nonprofit entity operates under the umbrella of the University of Utah and specializes in a wide array of more than 3,000 tests. These range from standard screenings to highly specialized molecular and genetic assays. Clients include top-tier university hospitals, government facilities, and private clinics.
ARUP's Institute for Research and Innovation in Diagnostic and Precision Medicine continues to spearhead innovations in laboratory research. As an ISO 15189 CAP accredited laboratory, ARUP emphasizes quality and accuracy in their services, ensuring they remain at the forefront of diagnostic medicine.
Frequently Asked Questions
What is the purpose of the new assay launched by ARUP?
The new assay is designed to detect and subtype the influenza A (H5) virus, aiding in the evaluation of individuals exposed to avian influenza.
How has ARUP collaborated with the CDC?
ARUP has worked with the CDC to validate their new test for avian influenza, ensuring its effectiveness in public health responses.
What is the significance of monitoring H5N1 outbreaks?
Monitoring H5N1 outbreaks is critical for preventing human infections, as these cases can arise from contact with infected animals.
Who can benefit from ARUP’s testing services?
ARUP’s testing services are available to a variety of clients, including hospitals, government facilities, and clinics across the nation.
What future developments can we expect from ARUP?
ARUP plans to continue refining their testing capabilities and monitoring emerging pathogens to enhance public health responses.
